NasdaqGM:LGNDPharmaceuticals
A Look At Ligand Pharmaceuticals (LGND) Valuation After Profitability Return And Reaffirmed 2026 Guidance
Ligand Pharmaceuticals (LGND) is back in focus after reporting quarterly and full year 2025 results that moved from loss to profit, reaffirming 2026 revenue guidance and filing new shelf and at the market equity programs.
See our latest analysis for Ligand Pharmaceuticals.
Ligand’s recent swing to profitability, reaffirmed 2026 revenue guidance and fresh shelf and at the market programs have come after a period of solid momentum. The current US$201.90 share price sits against a 90 day share...